“Proton therapy planning and image-guidance strategies within a randomized controlled trial for high-risk prostate cancer”
Extract from abstract: The Danish Prostate Cancer Group is launching the randomized trial, PROstate PROTON Trial 1 (NCT05350475), that compares photons and protons to the prostate and pelvic lymph nodes in treatment of high-risk prostate cancer. The aim of the work described in this paper was, in preparation of this trial, to establish a strategy for conventionally fractionated proton therapy of prostate and elective pelvic lymph nodes that is feasible and robust. Proton treatments are image-guided based on gold fiducial markers and on-board imaging systems in line with current practice.
Extract from Materials and methods: … Patients in both treatment arms have fiducial markers (Gold Anchor, Naslund Medical AB, Huddinge, Sweden) for image-guidance… The compatibility of Gold Anchor fiducial markers with proton therapy was determined based on visibility and contrast in the imaging modalities shown in Fig. 1 as well as the absence of shadowing effects and dose degradations downstream of the implanted markers in the relevant clinical beam configuration [32].
Article from Clinical and Translational Radiation Oncology, 2023